24314 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 08
11:28 UTC
|
CNQ
Canadian Natural Resources
|
◎ Target | firm only | Outperform | C$65.00→ C$66.00+1.5% |
|
Aug 08
11:28 UTC
|
CNQ
Canadian Natural Resources
|
◎ Target | firm only | Buy | C$72.00→ C$73.00+1.4% |
|
Aug 08
11:28 UTC
|
CNQ
Canadian Natural Resources
|
◎ Target | firm only | Sec→ r Perform | C$71.00→ C$73.00+2.8% |
|
Aug 08
11:28 UTC
|
CMPX
Compass Therapeutics
|
◎ Target | Biren Amin ★☆☆☆☆ #3025 | Overweight | $4.00→ $6.00+50.0% |
|
Aug 08
11:28 UTC
|
CMPS
Compass Pathways
|
◎ Target | Patrick R. Trucchio not yet tracked | Buy | $70.00→ $65.00-7.1% |
|
Aug 08
11:28 UTC
|
CMC
Commercial Metals
|
◎ Target | Richard Garchitorena ★★★☆☆ #1335 | Equal Weight | $75.00→ $80.00+6.7% |
|
Aug 08
11:28 UTC
|
CLYM
Climb Bio
|
◎ Target | Danielle Brill ★★★☆☆ #1082 | Buy | $17.00→ $25.00+47.1% |
|
Aug 08
11:28 UTC
|
CLS
Celestica
|
◎ Target | Tim Long ★★★☆☆ #1066 | Overweight | $430.00→ $406.00-5.6% |
|
Aug 08
11:28 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Etzer Darout ★★★☆☆ #1004 | Overweight | $48.00→ $53.00+10.4% |
|
Aug 08
11:28 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Judah Frommer ★★★★☆ #865 | Overweight | $40.00→ $46.00+15.0% |
|
Aug 08
11:28 UTC
|
CIFR
Cipher Mining
|
◎ Target | Richard Choe ★★★☆☆ #2092 | Overweight | $23.00→ $22.00-4.3% |
|
Aug 08
11:28 UTC
|
CHYM
Chime Financial
|
◎ Target | Nik Cremo ★★★☆☆ #2010 | Overweight | $26.00→ $33.00+26.9% |
|
Aug 08
11:28 UTC
|
CGON
CG Oncology
|
◎ Target | Leonid Timashev ★★★★☆ #485 | Outperform | $81.00→ $79.00-2.5% |
|
Aug 08
11:28 UTC
|
CGON
CG Oncology
|
◎ Target | Kelsey Goodwin ★★★☆☆ #1556 | Overweight | $82.00→ $85.00+3.7% |
|
Aug 08
11:28 UTC
|
CGON
CG Oncology
|
◎ Target | Gregory Renza ★★★☆☆ #1756 | Buy | $82.00→ $85.00+3.7% |
|
Aug 08
11:28 UTC
|
CGNX
Cognex
|
◎ Target | Jamie Cook ★★★☆☆ #1171 | Hold | $71.00→ $78.00+9.9% |
|
Aug 08
11:28 UTC
|
CGNX
Cognex
|
◎ Target | Troy Jensen ★★★★☆ #779 | Overweight | $76.00→ $84.00+10.5% |
|
Aug 08
11:28 UTC
|
CGNX
Cognex
|
◎ Target | James Ricchiuti ★★★★☆ #853 | Buy | $75.00→ $80.00+6.7% |
|
Aug 08
11:28 UTC
|
CF
CF Industries
|
◎ Target | Joshua Spector ★★★☆☆ #1750 | Neutral | $115.00→ $123.00+7.0% |
|
Aug 08
11:28 UTC
|
CELH
Celsius
|
◎ Target | Andrea Teixeira not yet tracked | Overweight | $56.00→ $52.00-7.1% |
|
Aug 08
11:28 UTC
|
CELH
Celsius
|
◎ Target | Filippo Falorni ★★★★☆ #585 | Buy | $50.00→ $40.00-20.0% |
|
Aug 08
11:28 UTC
|
CELH
Celsius
|
◎ Target | Michael Lavery ★★★☆☆ #1746 | Overweight | $49.00→ $36.00-26.5% |
|
Aug 08
11:28 UTC
|
CDRE
Cadre
|
◎ Target | Tomohiko Sano ★★★☆☆ #1580 | Overweight | $40.00→ $45.00+12.5% |
|
Aug 08
11:28 UTC
|
CCOI
Cogent Communications
|
◎ Target | Gregory Williams ★☆☆☆☆ #2982 | Buy | $34.00→ $30.00-11.8% |
|
Aug 08
11:28 UTC
|
CCOI
Cogent Communications
|
◎ Target | Eric Luebchow ★★☆☆☆ #2553 | Equal Weight | $18.00→ $14.00-22.2% |
|
Aug 08
11:28 UTC
|
CCOI
Cogent Communications
|
◎ Target | Brandon Nispel ★★★☆☆ #1470 | Overweight | $25.00→ $15.00-40.0% |
|
Aug 08
11:28 UTC
|
CBT
Cabot
|
◎ Target | Jeffrey Zekauskas ★★☆☆☆ #2637 | Underweight | $70.00→ $78.00+11.4% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Deepak Mathivanan ★★★☆☆ #2169 | Overweight | $56.00→ $63.00+12.5% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Bernie McTernan ★★★☆☆ #2193 | Buy | $55.00→ $63.00+14.5% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Jason Helfstein ★★☆☆☆ #2563 | Outperform | $60.00→ $65.00+8.3% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Ken Gawrelski ★★★☆☆ #1180 | Equal Weight | $47.00→ $54.00+14.9% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Taylor Manley not yet tracked | Neutral | $44.00→ $46.00+4.5% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Doug Anmuth ★★☆☆☆ #2474 | Overweight | $55.00→ $62.00+12.7% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Mark Zgutowicz ★★★☆☆ #1862 | Buy | $55.00→ $63.00+14.5% |
|
Aug 08
11:28 UTC
|
CART
Maplebear
|
◎ Target | Ross Sandler ★★☆☆☆ #2248 | Overweight | $69.00→ $77.00+11.6% |
|
Aug 08
11:28 UTC
|
CARS
Cars.com
|
◎ Target | Joseph Spak ★★★☆☆ #1103 | Neutral | $12.00→ $13.00+8.3% |
|
Aug 08
11:28 UTC
|
CARG
CarGurus
|
◎ Target | Brad Erickson ★★☆☆☆ #2287 | Outperform | $35.00→ $42.00+20.0% |
|
Aug 08
11:28 UTC
|
CARG
CarGurus
|
◎ Target | Kunal Madhukar ★★☆☆☆ #2483 | Neutral | $37.00→ $40.00+8.1% |
|
Aug 08
11:28 UTC
|
CARG
CarGurus
|
◎ Target | Marvin Fong ★★☆☆☆ #2509 | Buy | $40.00→ $41.00+2.5% |
|
Aug 08
11:28 UTC
|
CARG
CarGurus
|
◎ Target | Chris Pierce ★☆☆☆☆ #3085 | Buy | $43.00→ $44.00+2.3% |
|
Aug 08
11:28 UTC
|
CACI
CACI International
|
◎ Target | Gavin Parsons ★★★★☆ #837 | Buy | $598.00→ $804.00+34.4% |
|
Aug 08
11:28 UTC
|
CACI
CACI International
|
◎ Target | Seth Seifman ★★★☆☆ #1247 | Overweight | $645.00→ $715.00+10.9% |
|
Aug 08
11:28 UTC
|
CABO
Cable One
|
◎ Target | Gregory Williams ★☆☆☆☆ #2982 | Hold | $111.00→ $86.00-22.5% |
|
Aug 08
11:28 UTC
|
BTMD
biote
|
◎ Target | Jonna Kim ★★★★★ #283 | Buy | $2.50→ $2.00-20.0% |
|
Aug 08
11:28 UTC
|
BSY
Bentley Systems
|
◎ Target | firm only | Outperform | $41.00→ $43.00+4.9% |
|
Aug 08
11:28 UTC
|
BP
BP
|
◎ Target | John Royall not yet tracked | Neutral | $42.00→ $43.00+2.4% |
|
Aug 08
11:28 UTC
|
BOS
AirBoss of America
|
◎ Target | firm only | Buy | C$10.00→ C$11.00+10.0% |
|
Aug 08
11:28 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Mitchell S. Kapoor not yet tracked | Neutral | $50.00→ $60.00+20.0% |
|
Aug 08
11:28 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Leland Gershell ★★☆☆☆ #2394 | Outperform | $95.00→ $97.00+2.1% |
|
Aug 08
11:28 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Matthew Harrison not yet tracked | Overweight | $119.00→ $124.00+4.2% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.